CA3000040A1 - Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof - Google Patents

Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof Download PDF

Info

Publication number
CA3000040A1
CA3000040A1 CA3000040A CA3000040A CA3000040A1 CA 3000040 A1 CA3000040 A1 CA 3000040A1 CA 3000040 A CA3000040 A CA 3000040A CA 3000040 A CA3000040 A CA 3000040A CA 3000040 A1 CA3000040 A1 CA 3000040A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
hydroxy
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3000040A
Other languages
English (en)
French (fr)
Inventor
Xiaojin Zhang
Qidong You
Yonghua LEI
Tianhan HU
Xingsen WU
Haopeng Sun
Xiaoke Guo
Xiaoli Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CA3000040A1 publication Critical patent/CA3000040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3000040A 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof Abandoned CA3000040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510648342.9A CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN201510648342.9 2015-10-09
PCT/CN2015/095728 WO2017059623A1 (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CA3000040A1 true CA3000040A1 (en) 2017-04-13

Family

ID=54716523

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000040A Abandoned CA3000040A1 (en) 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof

Country Status (20)

Country Link
US (2) US10889546B2 (https=)
EP (1) EP3360862B1 (https=)
JP (1) JP6635562B2 (https=)
KR (1) KR20180063229A (https=)
CN (2) CN105130888A (https=)
AU (1) AU2015411258B2 (https=)
BR (1) BR112018005969A2 (https=)
CA (1) CA3000040A1 (https=)
DK (1) DK3360862T3 (https=)
ES (1) ES2794002T3 (https=)
HR (1) HRP20200907T1 (https=)
HU (1) HUE049409T2 (https=)
LT (1) LT3360862T (https=)
MX (1) MX379007B (https=)
PL (1) PL3360862T3 (https=)
PT (1) PT3360862T (https=)
RU (1) RU2692494C1 (https=)
SI (1) SI3360862T1 (https=)
UA (1) UA120407C2 (https=)
WO (1) WO2017059623A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
JP2021500315A (ja) * 2017-10-25 2021-01-07 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． アルキニルピリジンプロリル水酸化酵素阻害剤の結晶型及びその製造方法
CN110240562B (zh) * 2018-03-08 2022-04-12 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
CA3098564A1 (en) * 2018-05-24 2019-11-28 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Method for preparing alkynyl pyridine prolyl hydroxylase inhibitor
CN109593084B (zh) * 2019-01-23 2021-09-28 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
US20220160693A1 (en) * 2019-03-04 2022-05-26 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor
CN116670131A (zh) * 2020-08-14 2023-08-29 阿克比治疗有限公司 Phd抑制剂化合物、组合物和使用方法
CN112741834A (zh) * 2021-02-07 2021-05-04 复旦大学附属中山医院 HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途
CN116514710B (zh) * 2022-01-21 2024-07-05 中国药科大学 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW201141839A (en) * 2010-04-19 2011-12-01 Daiichi Sankyo Co Ltd Substituted 5-hydroxypyrimidine-4-carboxamide compounds
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
CN104024227B8 (zh) * 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Also Published As

Publication number Publication date
EP3360862B1 (en) 2020-04-22
KR20180063229A (ko) 2018-06-11
US20200407319A1 (en) 2020-12-31
HRP20200907T1 (hr) 2020-09-04
CN107848976B (zh) 2020-11-17
EP3360862A1 (en) 2018-08-15
CN105130888A (zh) 2015-12-09
AU2015411258B2 (en) 2020-09-17
US10889546B2 (en) 2021-01-12
WO2017059623A1 (zh) 2017-04-13
AU2015411258A1 (en) 2018-05-10
RU2692494C1 (ru) 2019-06-25
ES2794002T3 (es) 2020-11-17
CN107848976A (zh) 2018-03-27
MX379007B (es) 2025-03-11
UA120407C2 (uk) 2019-11-25
PT3360862T (pt) 2020-05-27
BR112018005969A2 (pt) 2018-10-16
DK3360862T3 (da) 2020-06-02
SI3360862T1 (sl) 2020-08-31
JP2018529690A (ja) 2018-10-11
HUE049409T2 (hu) 2020-10-28
EP3360862A4 (en) 2018-08-15
US20180305317A1 (en) 2018-10-25
JP6635562B2 (ja) 2020-01-29
LT3360862T (lt) 2020-07-10
HK1247613A1 (zh) 2018-09-28
MX2018003832A (es) 2018-06-18
PL3360862T3 (pl) 2020-09-21

Similar Documents

Publication Publication Date Title
CA3000040A1 (en) Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
US12312349B2 (en) Apoptosis-inducing agents
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
JP5569857B2 (ja) 二環式アシルグアニジン誘導体
FI92190C (fi) Menetelmä farmakologisesti arvokkaan indaanijohdannaisen valmistamiseksi
CA2517446A1 (en) 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists
CN106632245A (zh) 氮取代基苯基吡唑类黄嘌呤氧化还原酶抑制剂及制备与应用
KR20160005347A (ko) α-치환 글라이신아마이드 유도체
CN106397408B (zh) 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途
CN107922374A (zh) 新型儿茶酚衍生物及含有它的药物组合物
CN102603553A (zh) 具有协同抗真菌作用的化合物及其在药学中的用途
HK1247613B (zh) 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN117126153A (zh) 一种新冠病毒抑制剂，其制备方法和其药物组合物与用途
US20180064665A1 (en) N-phenyl-n'-phenoxycarbonyl-phenylsulfonhydrazide derivative and pharmaceutical composition comprising the same
US20070032522A1 (en) Antiviral agents
JP2009149571A (ja) 鎖状アミン化合物を含有する医薬
CN115093444B (zh) 一种萘磺酰胺磷酸酯类小分子化合物及其应用
EP4389121A1 (en) Antiviral amino acid derivatives
HK40082282B (en) Apoptosis-inducing agents
HK40082282A (en) Apoptosis-inducing agents
CN120227374A (zh) 一种rsv病毒抑制剂
CN115677703A (zh) 吡啶酮类化合物及其用途
CN121159584A (zh) 一种用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途
WO2012038905A1 (fr) Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200901

FZDE Discontinued

Effective date: 20240109